Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics' stock price has experienced significant volatility, with a substantial decline over the past six months and twelve months. Key events impacting the stock include the Q4 2025 earnings release, the end-of-Phase 2 FDA meeting for CAD-1005, positive Phase 2 results for CAD-1005, and the Q3 2025 earnings release. Analyst forecasts suggest a potential significant upside, but also note execution risk and concerns about financial runway and dilution risk.

There is no information available to suggest any demand seasonality for Cadrenal Therapeutics, Inc.'s products or services. As a clinical-stage biopharmaceutical company, its products are still in development and have not yet reached commercialization.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing anticoagulant therapies for rare and high-risk patient populations. Their lead product candidate is tecarfarin, an oral vitamin K antagonist anticoagulant in Phase 3 development. They are also developing CAD-1005, a Phase 2 12-LOX Inhibitor for heparin-induced thrombocytopenia (HIT), and frunexian, a Phase II-ready intravenous Factor XIa inhibitor for acute care settings.

Cadrenal Therapeutics is headquartered in Ponte Vedra, Florida, United States. While CAD-1005 has potential market interest in Europe due to orphan drug status from the European Medicines Agency, the company's primary focus is within the United States.

Cadrenal Therapeutics' reputation has been shaped by its clinical development progress and financial standing. Positive developments include encouraging Phase 2 results for CAD-1005 and FDA designations. Challenges include the company's stock performance and analyst concerns regarding funding and execution risk associated with advancing to Phase 3 trials.

Cadrenal Therapeutics has a mixed ownership structure comprising institutional, retail, and individual investors. Retail investors hold the largest portion of the stock, followed by insiders. Major institutional owners and shareholders include Vanguard Group Inc, DRW Securities, LLC, and Geode Capital Management, Llc. Quang X. Pham, the CEO, owns the most shares among individual investors.